287 related articles for article (PubMed ID: 31652787)
1. Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia.
Jentzsch M; Schwind S; Bach E; Stasik S; Thiede C; Platzbecker U
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652787
[TBL] [Abstract][Full Text] [Related]
2. Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy.
Schwind S; Jentzsch M; Bach E; Stasik S; Thiede C; Platzbecker U
Curr Treat Options Oncol; 2020 Jan; 21(1):8. PubMed ID: 32002673
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia.
Ding Y; Liu Z; Wang H; Xiong S; Zhai Z
Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341
[TBL] [Abstract][Full Text] [Related]
4. Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
Pettit K; Stock W; Walter RB
Leuk Lymphoma; 2016 Jul; 57(7):1527-33. PubMed ID: 27269126
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease testing in acute myeloid leukaemia.
Hourigan CS; Gale RP; Gormley NJ; Ossenkoppele GJ; Walter RB
Leukemia; 2017 Jul; 31(7):1482-1490. PubMed ID: 28386105
[TBL] [Abstract][Full Text] [Related]
6. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
7. Measurable Residual Disease Analysis by Flow Cytometry and Correlation With Molecular Measurable Residual Disease in Acute Promyelocytic Leukemia: A Real-World Prospective Study.
Wen Z; Xue X; Li S; Liu Y; Jin Y; Jiang N; Liao H
Arch Pathol Lab Med; 2024 Jun; ():. PubMed ID: 38838353
[TBL] [Abstract][Full Text] [Related]
8. Methods of Detection of Measurable Residual Disease in AML.
Zhou Y; Wood BL
Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
[TBL] [Abstract][Full Text] [Related]
9. SOHO State of the Art Updates and Next Questions: Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid Leukemia.
Tedjaseputra A; Russell N; Dillon R
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38734498
[TBL] [Abstract][Full Text] [Related]
10. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
11. Evaluating measurable residual disease in acute myeloid leukemia.
Ravandi F; Walter RB; Freeman SD
Blood Adv; 2018 Jun; 2(11):1356-1366. PubMed ID: 29895626
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease in acute myeloid leukemia: coming of age.
Paietta E
Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease in acute myeloid leukaemia.
Hourigan CS; Karp JE
Nat Rev Clin Oncol; 2013 Aug; 10(8):460-71. PubMed ID: 23799371
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
15. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
Czyz A; Nagler A
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
Skou AS; Juul-Dam KL; Ommen HB; Hasle H
Br J Haematol; 2021 Nov; 195(3):310-327. PubMed ID: 33851435
[TBL] [Abstract][Full Text] [Related]
17. Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia-Real-World Context.
Patkar N; Kakirde C; Bhanshe P; Joshi S; Chaudhary S; Badrinath Y; Ghoghale S; Deshpande N; Kadechkar S; Chatterjee G; Kannan S; Shetty D; Gokarn A; Punatkar S; Bonda A; Nayak L; Jain H; Bagal B; Menon H; Sengar M; Khizer SH; Khattry N; Tembhare P; Gujral S; Subramanian P
Front Oncol; 2019; 9():450. PubMed ID: 31263671
[No Abstract] [Full Text] [Related]
18. Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.
Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf Å; Deneberg S; Jädersten M; Antunovic P; Cammenga J; Möllgård L; Wennström L; Ölander E; Ehinger M; Fogelstrand L; Höglund M; Lazarevic VL
Leuk Lymphoma; 2021 Aug; 62(8):1973-1981. PubMed ID: 33719843
[TBL] [Abstract][Full Text] [Related]
19. Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.
Roug AS; Ommen HB
Curr Treat Options Oncol; 2019 Mar; 20(4):28. PubMed ID: 30874904
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
